Skip to main
BNGO

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics demonstrated robust growth with a 17% increase in sales of nanochannel array flowcells in 2Q25, compared to the previous year, indicating heightened demand for its products. Additionally, the company reported an 11% year-over-year increase in combined revenue from consumables, software, and remaining services in 2Q25, driven by a notable 16% rise in consumables and software revenues. Furthermore, Bionano's expectations for new OGM installations for FY2025 have been raised to a range of 20-25, reflecting strong momentum and expanding utilization of its technology in emerging markets like Japan.

Bears say

Bionano Genomics faces significant risks that contribute to a negative outlook, including lower-than-expected market uptake and utilization of its products, which could hinder revenue growth. The company also struggles with potential difficulties in securing additional capital for operations, leading to dilution concerns for existing shareholders. Lastly, employing a conservative EV/Revenue multiple highlights the challenges in achieving favorable valuations amidst these operational uncertainties.

Bionano Genomics (BNGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Buy based on their latest research and market trends.

According to 3 analysts, Bionano Genomics (BNGO) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.